These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12435055)

  • 1. Technology evaluation: APC-80200, Dendreon.
    Rice A; Hart D
    Curr Opin Mol Ther; 2002 Oct; 4(5):523-7. PubMed ID: 12435055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technology evaluation: APC-8015, Dendreon.
    Rini BI
    Curr Opin Mol Ther; 2002 Feb; 4(1):76-9. PubMed ID: 11883698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technology evaluation: PROSTVAC, Therion.
    Doehn C; Jocham D
    Curr Opin Mol Ther; 2002 Oct; 4(5):528-34. PubMed ID: 12435056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DC in multiple myeloma immunotherapy.
    Turtle CJ; Brown RD; Joshua DE; Hart DN
    Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotypic vaccination as therapy for multiple myeloma.
    Kwak LW; Thielemans K; Massaia M
    Semin Hematol; 1999 Jan; 36(1 Suppl 3):34-7. PubMed ID: 9989488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technology evaluation: Onyvax-P, Onyvax.
    Doehn C; Böhmer T; Jocham D
    Curr Opin Mol Ther; 2005 Oct; 7(5):511-9. PubMed ID: 16248287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell fusion technology vaccine tested in kidney cancer clinical trial.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):620. PubMed ID: 12503204
    [No Abstract]   [Full Text] [Related]  

  • 8. Active immunotherapy of multiple myeloma.
    Houet L; Veelken H
    Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in multiple myeloma: current strategies and future prospects.
    Yi Q
    Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DC-based immunotherapy of B-cell malignancies.
    Reichardt VL; Brossart P
    Cytotherapy; 2004; 6(1):62-7. PubMed ID: 14985168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology evaluation: HSPPC-96, antigenics.
    Minev BR
    Curr Opin Mol Ther; 2003 Dec; 5(6):680-7. PubMed ID: 14755896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
    Leitch HA; Connors JM
    Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New advances in clinical trials of cancer vaccines].
    Peng F; Wei YQ
    Ai Zheng; 2006 Aug; 25(8):1059-62. PubMed ID: 16965694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials referral resource. Multiple myeloma and Waldenström's macroglobulinemia phase III trials.
    Cheson BD; Phillips PH
    Oncology (Williston Park); 1994 Jul; 8(7):45, 48-50. PubMed ID: 7917838
    [No Abstract]   [Full Text] [Related]  

  • 16. Technology evaluation: TroVax, Oxford BioMedica.
    Reinis M
    Curr Opin Mol Ther; 2004 Aug; 6(4):436-42. PubMed ID: 15468602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
    Klepin HD; Hurd DD
    Bone Marrow Transplant; 2006 Nov; 38(9):585-92. PubMed ID: 16953209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine strategies to treat lymphoproliferative disorders.
    Radford KJ; Vari F; Hart DN
    Pathology; 2005 Dec; 37(6):534-50. PubMed ID: 16373232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of idiotype vaccines in the treatment of human B-cell malignancies.
    Bendandi M
    Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.